(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Oil rises above $115 and Asia stocks slide as Iran war escalates - 2Native Americans had dice and games of probability long before other cultures, study finds
- 3What is the Significant Tech Expertise to Master Today?
- 4The most effective method to Succeed in Your Web based Advertising Degree: Procedures for Progress
- 5Investigate These Retreats Well known With Seniors
- An Aide On Upgrading Your FICO rating
- Astonishing interstellar comet captured in new images by NASA Mars missions
- Flourishing in a Cutthroat Work Market: Vocation Methodologies
- 'Home Alone' actor Joe Pesci said 'no' to this stunt until he saw a 9-year-old girl do it, says director Chris Columbus
- HGV driver recruited others to smuggle migrants
- Are Iraqi militias crossing into Iran to support Iran's war effort?
- Florence's Uffizi Gallery moves treasures to safety after cyberattack
- Ukraine apologizes to Finland for crashed drones
- The Green Transformation: 5 Feasible Living Practices
